請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/25300
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 許金玉 | |
dc.contributor.author | Jiun-Han Lin | en |
dc.contributor.author | 林君翰 | zh_TW |
dc.date.accessioned | 2021-06-08T06:08:15Z | - |
dc.date.copyright | 2007-08-08 | |
dc.date.issued | 2007 | |
dc.date.submitted | 2007-07-18 | |
dc.identifier.citation | 1. Alimandi, M., A. Romano, M. C. Curia, R. Muraro, P. Fedi, S. A. Aaronson, P. P. Di Fiore, and M. H. Kraus. 1995. Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. Oncogene 10:1813-21.
2. Allred, D. C., G. M. Clark, R. Molina, A. K. Tandon, S. J. Schnitt, K. W. Gilchrist, C. K. Osborne, D. C. Tormey, and W. L. McGuire. 1992. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol 23:974-9. 3. Arbach, H., V. Viglasky, F. Lefeu, J. M. Guinebretiere, V. Ramirez, N. Bride, N. Boualaga, T. Bauchet, J. P. Peyrat, M. C. Mathieu, S. Mourah, M. P. Podgorniak, J. M. Seignerin, K. Takada, and I. Joab. 2006. Epstein-Barr virus (EBV) genome and expression in breast cancer tissue: effect of EBV infection of breast cancer cells on resistance to paclitaxel (Taxol). J Virol 80:845-53. 4. Baeza, N., J. Masuoka, P. Kleihues, and H. Ohgaki. 2003. AXIN1 mutations but not deletions in cerebellar medulloblastomas. Oncogene 22:632-6. 5. Bafico, A., G. Liu, L. Goldin, V. Harris, and S. A. Aaronson. 2004. An autocrine mechanism for constitutive Wnt pathway activation in human cancer cells. Cancer Cell 6:497-506. 6. Baumforth, K. R., J. R. Flavell, G. M. Reynolds, G. Davies, T. R. Pettit, W. Wei, S. Morgan, T. Stankovic, Y. Kishi, H. Arai, M. Nowakova, G. Pratt, J. Aoki, M. J. Wakelam, L. S. Young, and P. G. Murray. 2005. Induction of autotaxin by the Epstein-Barr virus promotes the growth and survival of Hodgkin lymphoma cells. Blood 106:2138-46. 7. Bobrow, L. G., R. R. Millis, L. C. Happerfield, and W. J. Gullick. 1997. c-erbB-3 protein expression in ductal carcinoma in situ of the breast. Eur J Cancer 33:1846-50. 8. Bonnet, M., J. M. Guinebretiere, E. Kremmer, V. Grunewald, E. Benhamou, G. Contesso, and I. Joab. 1999. Detection of Epstein-Barr virus in invasive breast cancers. J Natl Cancer Inst 91:1376-81. 9. Borza, C. M., and L. M. Hutt-Fletcher. 2002. Alternate replication in B cells and epithelial cells switches tropism of Epstein-Barr virus. Nat Med 8:594-9. 10. Borza, C. M., A. J. Morgan, S. M. Turk, and L. M. Hutt-Fletcher. 2004. Use of gHgL for attachment of Epstein-Barr virus to epithelial cells compromises infection. J Virol 78:5007-14. 11. Bukholm, I. K., J. M. Nesland, and A. L. Borresen-Dale. 2000. Re-expression of E-cadherin, alpha-catenin and beta-catenin, but not of gamma-catenin, in metastatic tissue from breast cancer patients [seecomments]. J Pathol 190:15-9. 12. Burkitt, D. 1962. Determining the climatic limitations of a children's cancer common in Africa. Br Med J 2:1019-23. 13. Burkitt, D. 1958. A sarcoma involving the jaws in African children. Br J Surg 46:218-23. 14. Caldwell, R. G., J. B. Wilson, S. J. Anderson, and R. Longnecker. 1998. Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. Immunity 9:405-11. 15. Chan, E. F., U. Gat, J. M. McNiff, and E. Fuchs. 1999. A common human skin tumour is caused by activating mutations in beta-catenin. Nat Genet 21:410-3. 16. Chang, Y., C. H. Tung, Y. T. Huang, J. Lu, J. Y. Chen, and C. H. Tsai. 1999. Requirement for cell-to-cell contact in Epstein-Barr virus infection of nasopharyngeal carcinoma cells and keratinocytes. J Virol 73:8857-66. 17. Chen, H. L., M. M. Lung, J. S. Sham, D. T. Choy, B. E. Griffin, and M. H. Ng. 1992. Transcription of BamHI-A region of the EBV genome in NPC tissues and B cells. Virology 191:193-201. 18. Cherney, B. W., C. Sgadari, C. Kanegane, F. Wang, and G. Tosato. 1998. Expression of the Epstein-Barr virus protein LMP1 mediates tumor regression in vivo. Blood 91:2491-500. 19. Chu, P. G., K. L. Chang, Y. Y. Chen, W. G. Chen, and L. M. Weiss. 2001. No significant association of Epstein-Barr virus infection with invasive breast carcinoma. Am J Pathol 159:571-8. 20. Chuang, T. C., Y. J. Lee, J. Y. Liu, Y. S. Lin, J. W. Li, V. Wang, S. L. Law, and M. C. Kao. 2003. EBNA1 may prolong G(2)/M phase and sensitize HER2/neu-overexpressing ovarian cancer cells to both topoisomerase II-targeting and paclitaxel drugs. Biochem Biophys Res Commun 307:653-9. 21. Chuang, T. C., T. D. Way, Y. S. Lin, Y. C. Lee, S. L. Law, and M. C. Kao. 2002. The Epstein-Barr virus nuclear antigen-1 may act as a transforming suppressor of the HER2/neu oncogene. FEBS Lett 532:135-42. 22. Chung, G. G., M. P. Zerkowski, I. T. Ocal, M. Dolled-Filhart, J. Y. Kang, A. Psyrri, R. L. Camp, and D. L. Rimm. 2004. beta-Catenin and p53 analyses of a breast carcinoma tissue microarray. Cancer 100:2084-92. 23. Citri, A., K. B. Skaria, and Y. Yarden. 2003. The deaf and the dumb: the biology of ErbB-2 and ErbB-3. Exp Cell Res 284:54-65. 24. Cowin, P., T. M. Rowlands, and S. J. Hatsell. 2005. Cadherins and catenins in breast cancer. Curr Opin Cell Biol 17:499-508. 25. Dadmanesh, F., J. L. Peterse, A. Sapino, A. Fonelli, and V. Eusebi. 2001. Lymphoepithelioma-like carcinoma of the breast: lack of evidence of Epstein-Barr virus infection. Histopathology 38:54-61. 26. Dahmen, R. P., A. Koch, D. Denkhaus, J. C. Tonn, N. Sorensen, F. Berthold, J. Behrens, W. Birchmeier, O. D. Wiestler, and T. Pietsch. 2001. Deletions of AXIN1, a component of the WNT/wingless pathway, in sporadic medulloblastomas. Cancer Res 61:7039-43. 27. Danve, C., G. Decaussin, P. Busson, and T. Ooka. 2001. Growth transformation of primary epithelial cells with a NPC-derived Epstein-Barr virus strain. Virology 288:223-35. 28. de Villiers, E. M., R. E. Sandstrom, H. zur Hausen, and C. E. Buck. 2005. Presence of papillomavirus sequences in condylomatous lesions of the mamillae and in invasive carcinoma of the breast. Breast Cancer Res 7:R1-11. 29. Deacon, E. M., G. Pallesen, G. Niedobitek, J. Crocker, L. Brooks, A. B. Rickinson, and L. S. Young. 1993. Epstein-Barr virus and Hodgkin's disease: transcriptional analysis of virus latency in the malignant cells. J Exp Med 177:339-49. 30. Deshpande, C. G., S. Badve, N. Kidwai, and R. Longnecker. 2002. Lack of expression of the Epstein-Barr Virus (EBV) gene products, EBERs, EBNA1, LMP1, and LMP2A, in breast cancer cells. Lab Invest 82:1193-9. 31. Ding, Q., W. Xia, J. C. Liu, J. Y. Yang, D. F. Lee, J. Xia, G. Bartholomeusz, Y. Li, Y. Pan, Z. Li, R. C. Bargou, J. Qin, C. C. Lai, F. J. Tsai, C. H. Tsai, and M. C. Hung. 2005. Erk associates with and primes GSK-3beta for its inactivation resulting in upregulation of beta-catenin. Mol Cell 19:159-70. 32. Dolcetti, R., and J. Menezes. 2003. Epstein-Barr virus and undifferentiated nasopharyngeal carcinoma: new immunobiological and molecular insights on a long-standing etiopathogenic association. Adv Cancer Res 87:127-57. 33. Eliopoulos, A. G., N. J. Gallagher, S. M. Blake, C. W. Dawson, and L. S. Young. 1999. Activation of the p38 mitogen-activated protein kinase pathway by Epstein-Barr virus-encoded latent membrane protein 1 coregulates interleukin-6 and interleukin-8 production. J Biol Chem 274:16085-96. 34. Eliopoulos, A. G., M. Stack, C. W. Dawson, K. M. Kaye, L. Hodgkin, S. Sihota, M. Rowe, and L. S. Young. 1997. Epstein-Barr virus-encoded LMP1 and CD40 mediate IL-6 production in epithelial cells via an NF-kappaB pathway involving TNF receptor-associated factors. Oncogene 14:2899-916. 35. Eliopoulos, A. G., and L. S. Young. 2001. LMP1 structure and signal transduction. Semin Cancer Biol 11:435-44. 36. Epstein, M. A., B. G. Achong, and Y. M. Barr. 1964. Virus Particles in Cultured Lymphoblasts from Burkitt's Lymphoma. Lancet 15:702-3. 37. Evans, A. S. 1971. The spectrum of infections with Epstein-Barr virus: a hypothesis. J Infect Dis 124:330-7. 38. Everly, D. N., Jr., S. Kusano, and N. Raab-Traub. 2004. Accumulation of cytoplasmic beta-catenin and nuclear glycogen synthase kinase 3beta in Epstein-Barr virus-infected cells. J Virol 78:11648-55. 39. Fina, F., S. Romain, L. Ouafik, J. Palmari, F. Ben Ayed, S. Benharkat, P. Bonnier, F. Spyratos, J. A. Foekens, C. Rose, M. Buisson, H. Gerard, M. O. Reymond, J. M. Seigneurin, and P. M. Martin. 2001. Frequency and genome load of Epstein-Barr virus in 509 breast cancers from different geographical areas. Br J Cancer 84:783-90. 40. Fries, K. L., T. B. Sculley, J. Webster-Cyriaque, P. Rajadurai, R. H. Sadler, and N. Raab-Traub. 1997. Identification of a novel protein encoded by the BamHI A region of the Epstein-Barr virus. J Virol 71:2765-71. 41. Fukuda, M., and R. Longnecker. 2004. Latent membrane protein 2A inhibits transforming growth factor-beta 1-induced apoptosis through the phosphatidylinositol 3-kinase/Akt pathway. J Virol 78:1697-705. 42. Gaffey, M. J., H. F. Frierson, Jr., S. E. Mills, J. C. Boyd, R. J. Zarbo, J. F. Simpson, L. K. Gross, and L. M. Weiss. 1993. Medullary carcinoma of the breast. Identification of lymphocyte subpopulations and their significance. Mod Pathol 6:721-8. 43. Gayther, S. A., P. Barski, S. J. Batley, L. Li, K. A. de Foy, S. N. Cohen, B. A. Ponder, and C. Caldas. 1997. Aberrant splicing of the TSG101 and FHIT genes occurs frequently in multiple malignancies and in normal tissues and mimics alterations previously described in tumours. Oncogene 15:2119-26. 44. Gilligan, K., H. Sato, P. Rajadurai, P. Busson, L. Young, A. Rickinson, T. Tursz, and N. Raab-Traub. 1990. Novel transcription from the Epstein-Barr virus terminal EcoRI fragment, DIJhet, in a nasopharyngeal carcinoma. J Virol 64:4948-56. 45. Gilligan, K. J., P. Rajadurai, J. C. Lin, P. Busson, M. Abdel-Hamid, U. Prasad, T. Tursz, and N. Raab-Traub. 1991. Expression of the Epstein-Barr virus BamHI A fragment in nasopharyngeal carcinoma: evidence for a viral protein expressed in vivo. J Virol 65:6252-9. 46. Gires, O., S. Pockl, R. D. Chapman, and M. Munz. 2004. Targeted gene expression using a 1.1 kilobase promoter fragment of the tumour-associated antigen EpCAM. Anticancer Res 24:3715-21. 47. Glaser, S. L., R. F. Ambinder, J. A. DiGiuseppe, P. L. Horn-Ross, and J. L. Hsu. 1998. Absence of Epstein-Barr virus EBER-1 transcripts in an epidemiologically diverse group of breast cancers. Int J Cancer 75:555-8. 48. Glaser, S. L., J. L. Hsu, and M. L. Gulley. 2004. Epstein-Barr virus and breast cancer: state of the evidence for viral carcinogenesis. Cancer Epidemiol Biomarkers Prev 13:688-97. 49. Gottardi, C. J., and B. M. Gumbiner. 2001. Adhesion signaling: how beta-catenin interacts with its partners. Curr Biol 11:R792-4. 50. Gottardi, C. J., and B. M. Gumbiner. 2004. Distinct molecular forms of beta-catenin are targeted to adhesive or transcriptional complexes. J Cell Biol 167:339-49. 51. Grinstein, S., M. V. Preciado, P. Gattuso, P. A. Chabay, W. H. Warren, E. De Matteo, and V. E. Gould. 2002. Demonstration of Epstein-Barr virus in carcinomas of various sites. Cancer Res 62:4876-8. 52. Grossman, S. R., E. Johannsen, X. Tong, R. Yalamanchili, and E. Kieff. 1994. The Epstein-Barr virus nuclear antigen 2 transactivator is directed to response elements by the J kappa recombination signal binding protein. Proc Natl Acad Sci U S A 91:7568-72. 53. Guerreiro-Cacais, A. O., L. Li, D. Donati, M. T. Bejarano, A. Morgan, M. G. Masucci, L. Hutt-Fletcher, and V. Levitsky. 2004. Capacity of Epstein-Barr virus to infect monocytes and inhibit their development into dendritic cells is affected by the cell type supporting virus replication. J Gen Virol 85:2767-78. 54. Guy, P. M., J. V. Platko, L. C. Cantley, R. A. Cerione, and K. L. Carraway, 3rd. 1994. Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. Proc Natl Acad Sci U S A 91:8132-6. 55. Hammerschmidt, W., and B. Sugden. 1989. Genetic analysis of immortalizing functions of Epstein-Barr virus in human B lymphocytes. Nature 340:393-7. 56. Hatsell, S., T. Rowlands, M. Hiremath, and P. Cowin. 2003. Beta-catenin and Tcfs in mammary development and cancer. J Mammary Gland Biol Neoplasia 8:145-58. 57. He, T. C., T. A. Chan, B. Vogelstein, and K. W. Kinzler. 1999. PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 99:335-45. 58. He, T. C., A. B. Sparks, C. Rago, H. Hermeking, L. Zawel, L. T. da Costa, P. J. Morin, B. Vogelstein, and K. W. Kinzler. 1998. Identification of c-MYC as a target of the APC pathway. Science 281:1509-12. 59. Henderson, E., G. Miller, J. Robinson, and L. Heston. 1977. Efficiency of transformation of lymphocytes by Epstein-Barr virus. Virology 76:152-63. 60. Henderson, S., M. Rowe, C. Gregory, D. Croom-Carter, F. Wang, R. Longnecker, E. Kieff, and A. Rickinson. 1991. Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell 65:1107-15. 61. Hermanto, U., C. S. Zong, and L. H. Wang. 2001. ErbB2-overexpressing human mammary carcinoma cells display an increased requirement for the phosphatidylinositol 3-kinase signaling pathway in anchorage-independent growth. Oncogene 20:7551-62. 62. Herrmann, K., and G. Niedobitek. 2003. Lack of evidence for an association of Epstein-Barr virus infection with breast carcinoma. Breast Cancer Res 5:R13-7. 63. Hitt, M. M., M. J. Allday, T. Hara, L. Karran, M. D. Jones, P. Busson, T. Tursz, I. Ernberg, and B. E. Griffin. 1989. EBV gene expression in an NPC-related tumour. Embo J 8:2639-51. 64. Holbro, T., R. R. Beerli, F. Maurer, M. Koziczak, C. F. Barbas, 3rd, and N. E. Hynes. 2003. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci U S A 100:8933-8. 65. Horikawa, T., T. S. Sheen, H. Takeshita, H. Sato, M. Furukawa, and T. Yoshizaki. 2001. Induction of c-Met proto-oncogene by Epstein-Barr virus latent membrane protein-1 and the correlation with cervical lymph node metastasis of nasopharyngeal carcinoma. Am J Pathol 159:27-33. 66. Horiuchi, K., K. Mishima, M. Ohsawa, and K. Aozasa. 1994. Carcinoma of stomach and breast with lymphoid stroma: localisation of Epstein-Barr virus. J Clin Pathol 47:538-40. 67. Hsieh, J. J., and S. D. Hayward. 1995. Masking of the CBF1/RBPJ kappa transcriptional repression domain by Epstein-Barr virus EBNA2. Science 268:560-3. 68. Huang, J., H. Chen, L. Hutt-Fletcher, R. F. Ambinder, and S. D. Hayward. 2003. Lytic viral replication as a contributor to the detection of Epstein-Barr virus in breast cancer. J Virol 77:13267-74. 69. Huang, S., D. Stupack, A. Liu, D. Cheresh, and G. R. Nemerow. 2000. Cell growth and matrix invasion of EBV-immortalized human B lymphocytes is regulated by expression of alpha(v) integrins. Oncogene 19:1915-23. 70. Hudelist, G., C. F. Singer, M. Manavi, K. Pischinger, E. Kubista, and K. Czerwenka. 2003. Co-expression of ErbB-family members in human breast cancer: Her-2/neu is the preferred dimerization candidate in nodal-positive tumors. Breast Cancer Res Treat 80:353-61. 71. Humme, S., G. Reisbach, R. Feederle, H. J. Delecluse, K. Bousset, W. Hammerschmidt, and A. Schepers. 2003. The EBV nuclear antigen 1 (EBNA1) enhances B cell immortalization several thousandfold. Proc Natl Acad Sci U S A 100:10989-94. 72. Iezzoni, J. C., M. J. Gaffey, and L. M. Weiss. 1995. The role of Epstein-Barr virus in lymphoepithelioma-like carcinomas. Am J Clin Pathol 103:308-15. 73. Imai, S., J. Nishikawa, and K. Takada. 1998. Cell-to-cell contact as an efficient mode of Epstein-Barr virus infection of diverse human epithelial cells. J Virol 72:4371-8. 74. Imbert, A., R. Eelkema, S. Jordan, H. Feiner, and P. Cowin. 2001. Delta N89 beta-catenin induces precocious development, differentiation, and neoplasia in mammary gland. J Cell Biol 153:555-68. 75. Iwakiri, D., Y. Eizuru, M. Tokunaga, and K. Takada. 2003. Autocrine growth of Epstein-Barr virus-positive gastric carcinoma cells mediated by an Epstein-Barr virus-encoded small RNA. Cancer Res 63:7062-7. 76. Iwakiri, D., T. S. Sheen, J. Y. Chen, D. P. Huang, and K. Takada. 2005. Epstein-Barr virus-encoded small RNA induces insulin-like growth factor 1 and supports growth of nasopharyngeal carcinoma-derived cell lines. Oncogene 24:1767-73. 77. Jang, K. L., J. Shackelford, S. Y. Seo, and J. S. Pagano. 2005. Up-regulation of beta-catenin by a viral oncogene correlates with inhibition of the seven in absentia homolog 1 in B lymphoma cells. Proc Natl Acad Sci U S A 102:18431-6. 78. Jenson, H. B., C. T. Leach, K. L. McClain, V. V. Joshi, B. H. Pollock, R. T. Parmley, E. G. Chadwick, and S. B. Murphy. 1997. Benign and malignant smooth muscle tumors containing Epstein-Barr virus in children with AIDS. Leuk Lymphoma 27:303-14. 79. Karran, L., Y. Gao, P. R. Smith, and B. E. Griffin. 1992. Expression of a family of complementary-strand transcripts in Epstein-Barr virus-infected cells. Proc Natl Acad Sci U S A 89:8058-62. 80. Kassis, J., A. Maeda, N. Teramoto, K. Takada, C. Wu, G. Klein, and A. Wells. 2002. EBV-expressing AGS gastric carcinoma cell sublines present increased motility and invasiveness. Int J Cancer 99:644-51. 81. Kaye, K. M., K. M. Izumi, and E. Kieff. 1993. Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. Proc Natl Acad Sci U S A 90:9150-4. 82. Kerr, B. M., A. L. Lear, M. Rowe, D. Croom-Carter, L. S. Young, S. M. Rookes, P. H. Gallimore, and A. B. Rickinson. 1992. Three transcriptionally distinct forms of Epstein-Barr virus latency in somatic cell hybrids: cell phenotype dependence of virus promoter usage. Virology 187:189-201. 83. Kieff, E., and A. B. Rickinson. 2001. Epstein-Barr virus, p. 2511-2573. In D. M. Knipe and P. M. Howley (ed.), Fields' virology, 4 th ed. Lippincott Williams & Wilkins, Philadelphia, Pa. 84. Kienzle, N., M. Buck, S. Greco, K. Krauer, and T. B. Sculley. 1999. Epstein-Barr virus-encoded RK-BARF0 protein expression. J Virol 73:8902-6. 85. Kienzle, N., T. B. Sculley, L. Poulsen, M. Buck, S. Cross, N. Raab-Traub, and R. Khanna. 1998. Identification of a cytotoxic T-lymphocyte response to the novel BARF0 protein of Epstein-Barr virus: a critical role for antigen expression. J Virol 72:6614-20. 86. Kilger, E., A. Kieser, M. Baumann, and W. Hammerschmidt. 1998. Epstein-Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor. Embo J 17:1700-9. 87. Klapper, L. N., S. Glathe, N. Vaisman, N. E. Hynes, G. C. Andrews, M. Sela, and Y. Yarden. 1999. The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proc Natl Acad Sci U S A 96:4995-5000. 88. Klapper, L. N., M. H. Kirschbaum, M. Sela, and Y. Yarden. 2000. Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv Cancer Res 77:25-79. 89. Koh, T. J., C. J. Bulitta, J. V. Fleming, G. J. Dockray, A. Varro, and T. C. Wang. 2000. Gastrin is a target of the beta-catenin/TCF-4 growth-signaling pathway in a model of intestinal polyposis. J Clin Invest 106:533-9. 90. Komano, J., S. Maruo, K. Kurozumi, T. Oda, and K. Takada. 1999. Oncogenic role of Epstein-Barr virus-encoded RNAs in Burkitt's lymphoma cell line Akata. J Virol 73:9827-31. 91. Korinek, V., N. Barker, P. J. Morin, D. van Wichen, R. de Weger, K. W. Kinzler, B. Vogelstein, and H. Clevers. 1997. Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. Science 275:1784-7. 92. Kusano, S., and N. Raab-Traub. 2001. An Epstein-Barr virus protein interacts with Notch. J Virol 75:384-95. 93. Labrecque, L. G., D. M. Barnes, I. S. Fentiman, and B. E. Griffin. 1995. Epstein-Barr virus in epithelial cell tumors: a breast cancer study. Cancer Res 55:39-45. 94. Laherty, C. D., H. M. Hu, A. W. Opipari, F. Wang, and V. M. Dixit. 1992. The Epstein-Barr virus LMP1 gene product induces A20 zinc finger protein expression by activating nuclear factor kappa B. J Biol Chem 267:24157-60. 95. Lespagnard, L., P. Cochaux, D. Larsimont, M. Degeyter, T. Velu, and R. Heimann. 1995. Absence of Epstein-Barr virus in medullary carcinoma of the breast as demonstrated by immunophenotyping, in situ hybridization and polymerase chain reaction. Am J Clin Pathol 103:449-52. 96. Levitskaya, J., M. Coram, V. Levitsky, S. Imreh, P. M. Steigerwald-Mullen, G. Klein, M. G. Kurilla, and M. G. Masucci. 1995. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature 375:685-8. 97. Li, Y., N. P. Mahajan, J. Webster-Cyriaque, P. Bhende, G. K. Hong, H. S. Earp, and S. Kenney. 2004. The C-mer gene is induced by Epstein-Barr virus immediate-early protein BRLF1. J Virol 78:11778-85. 98. Lin, S. Y., W. Xia, J. C. Wang, K. Y. Kwong, B. Spohn, Y. Wen, R. G. Pestell, and M. C. Hung. 2000. Beta-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression. Proc Natl Acad Sci U S A 97:4262-6. 99. Lo, A. K., K. W. Lo, S. W. Tsao, H. L. Wong, J. W. Hui, K. F. To, D. S. Hayward, Y. L. Chui, Y. L. Lau, K. Takada, and D. P. Huang. 2006. Epstein-Barr virus infection alters cellular signal cascades in human nasopharyngeal epithelial cells. Neoplasia 8:173-80. 100. Lu, J., S. Y. Chen, H. H. Chua, Y. S. Liu, Y. T. Huang, Y. Chang, J. Y. Chen, T. S. Sheen, and C. H. Tsai. 2000. Upregulation of tyrosine kinase TKT by the Epstein-Barr virus transactivator Zta. J Virol 74:7391-9. 101. Lu, J., H. H. Chua, S. Y. Chen, J. Y. Chen, and C. H. Tsai. 2003. Regulation of matrix metalloproteinase-1 by Epstein-Barr virus proteins. Cancer Res 63:256-62. 102. Lu, J., W. H. Lin, S. Y. Chen, R. Longnecker, S. C. Tsai, C. L. Chen, and C. H. Tsai. 2006. Syk tyrosine kinase mediates Epstein-Barr virus latent membrane protein 2A-induced cell migration in epithelial cells. J Biol Chem 281:8806-14. 103. Mann, K. P., D. Staunton, and D. A. Thorley-Lawson. 1985. Epstein-Barr virus-encoded protein found in plasma membranes of transformed cells. J Virol 55:710-20. 104. Mannick, J. B., J. I. Cohen, M. Birkenbach, A. Marchini, and E. Kieff. 1991. The Epstein-Barr virus nuclear protein encoded by the leader of the EBNA RNAs is important in B-lymphocyte transformation. J Virol 65:6826-37. 105. McCall, S. A., J. H. Lichy, K. E. Bijwaard, N. S. Aguilera, W. S. Chu, and J. K. Taubenberger. 2001. Epstein-Barr virus detection in ductal carcinoma of the breast. J Natl Cancer Inst 93:148-50. 106. Michaelson, J. S., and P. Leder. 2001. beta-catenin is a downstream effector of Wnt-mediated tumorigenesis in the mammary gland. Oncogene 20:5093-9. 107. Miller, W. E., H. S. Earp, and N. Raab-Traub. 1995. The Epstein-Barr virus latent membrane protein 1 induces expression of the epidermal growth factor receptor. J Virol 69:4390-8. 108. Morin, P. J. 1999. beta-catenin signaling and cancer. Bioessays 21:1021-30. 109. Morrison, J. A., A. J. Klingelhutz, and N. Raab-Traub. 2003. Epstein-Barr virus latent membrane protein 2A activates beta-catenin signaling in epithelial cells. J Virol 77:12276-84. 110. Morrison, J. A., and N. Raab-Traub. 2005. Roles of the ITAM and PY motifs of Epstein-Barr virus latent membrane protein 2A in the inhibition of epithelial cell differentiation and activation of {beta}-catenin signaling. J Virol 79:2375-82. 111. Moser, A. R., E. M. Mattes, W. F. Dove, M. J. Lindstrom, J. D. Haag, and M. N. Gould. 1993. ApcMin, a mutation in the murine Apc gene, predisposes to mammary carcinomas and focal alveolar hyperplasias. Proc Natl Acad Sci U S A 90:8977-81. 112. Mosialos, G., M. Birkenbach, R. Yalamanchili, T. VanArsdale, C. Ware, and E. Kieff. 1995. The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell 80:389-99. 113. Murono, S., H. Inoue, T. Tanabe, I. Joab, T. Yoshizaki, M. Furukawa, and J. S. Pagano. 2001. Induction of cyclooxygenase-2 by Epstein-Barr virus latent membrane protein 1 is involved in vascular endothelial growth factor production in nasopharyngeal carcinoma cells. Proc Natl Acad Sci U S A 98:6905-10. 114. Murray, P. G., D. Lissauer, J. Junying, G. Davies, S. Moore, A. Bell, J. Timms, D. Rowlands, C. McConkey, G. M. Reynolds, S. Ghataura, D. England, R. Caroll, and L. S. Young. 2003. Reactivity with A monoclonal antibody to Epstein-Barr virus (EBV) nuclear antigen 1 defines a subset of aggressive breast cancers in the absence of the EBV genome. Cancer Res 63:2338-43. 115. Naidu, R., M. Yadav, S. Nair, and M. K. Kutty. 1998. Expression of c-erbB3 protein in primary breast carcinomas. Br J Cancer 78:1385-90. 116. Nanni, P., S. M. Pupa, G. Nicoletti, C. De Giovanni, L. Landuzzi, I. Rossi, A. Astolfi, C. Ricci, R. De Vecchi, A. M. Invernizzi, E. Di Carlo, P. Musiani, G. Forni, S. Menard, and P. L. Lollini. 2000. p185(neu) protein is required for tumor and anchorage-independent growth, not for cell proliferation of transgenic mammary carcinoma. Int J Cancer 87:186-94. 117. Nishikawa, J., S. Imai, T. Oda, T. Kojima, K. Okita, and K. Takada. 1999. Epstein-Barr virus promotes epithelial cell growth in the absence of EBNA2 and LMP1 expression. J Virol 73:1286-92. 118. Novak, A., and S. Dedhar. 1999. Signaling through beta-catenin and Lef/Tcf. Cell Mol Life Sci 56:523-37. 119. Olayioye, M. A., R. M. Neve, H. A. Lane, and N. E. Hynes. 2000. The ErbB signaling network: receptor heterodimerization in development and cancer. Embo J 19:3159-67. 120. Pagano, J. S., M. Blaser, M. A. Buendia, B. Damania, K. Khalili, N. Raab-Traub, and B. Roizman. 2004. Infectious agents and cancer: criteria for a causal relation. Semin Cancer Biol 14:453-71. 121. Parker, G. A., T. Crook, M. Bain, E. A. Sara, P. J. Farrell, and M. J. Allday. 1996. Epstein-Barr virus nuclear antigen (EBNA)3C is an immortalizing oncoprotein with similar properties to adenovirus E1A and papillomavirus E7. Oncogene 13:2541-9. 122. Parker, G. A., R. Touitou, and M. J. Allday. 2000. Epstein-Barr virus EBNA3C can disrupt multiple cell cycle checkpoints and induce nuclear division divorced from cytokinesis. Oncogene 19:700-9. 123. Pattengale, P. K., R. W. Smith, and P. Gerber. 1973. Selective transformation of B lymphocytes by E.B. virus. Lancet 2:93-4. 124. Pawlowski, V., F. Revillion, M. Hebbar, L. Hornez, and J. P. Peyrat. 2000. Prognostic value of the type I growth factor receptors in a large series of human primary breast cancers quantified with a real-time reverse transcription-polymerase chain reaction assay. Clin Cancer Res 6:4217-25. 125. Peifer, M., and P. Polakis. 2000. Wnt signaling in oncogenesis and embryogenesis--a look outside the nucleus. Science 287:1606-9. 126. Pennica, D., T. A. Swanson, J. W. Welsh, M. A. Roy, D. A. Lawrence, J. Lee, J. Brush, L. A. Taneyhill, B. Deuel, M. Lew, C. Watanabe, R. L. Cohen, M. F. Melhem, G. G. Finley, P. Quirke, A. D. Goddard, K. J. Hillan, A. L. Gurney, D. Botstein, and A. J. Levine. 1998. WISP genes are members of the connective tissue growth factor family that are up-regulated in wnt-1-transformed cells and aberrantly expressed in human colon tumors. Proc Natl Acad Sci U S A 95:14717-22. 127. Perkins, R. S. M., K. M. Sahm, C. B. Marando, D. M. Dickson-Witmer, G. R. M. Pahnke, M. M. Mitchell, N. J. M. Petrelli, I. D. Berkowitz, P. P. Soteropoulos, V. M. P. Aris, S. P. M. Dunn, and L. J. P. Krueger. 2006. Analysis of EBV reservoirs in paired blood and breast cancer primary biopsy specimens by real-time PCR. Breast Cancer Res 8:R70. 128. Perrigoue, J. G., J. A. den Boon, A. Friedl, M. A. Newton, P. Ahlquist, and B. Sugden. 2005. Lack of association between EBV and breast carcinoma. Cancer Epidemiol Biomarkers Prev 14:809-14. 129. Polakis, P. 2000. Wnt signaling and cancer. Genes Dev 14:1837-51. 130. Pope, J. H., M. K. Horne, and W. Scott. 1968. Transformation of foetal human keukocytes in vitro by filtrates of a human leukaemic cell line containing herpes-like virus. Int J Cancer 3:857-66. 131. Quinn, C. M., J. L. Ostrowski, S. A. Lane, D. P. Loney, J. Teasdale, and F. A. Benson. 1994. c-erbB-3 protein expression in human breast cancer: comparison with other tumour variables and survival. Histopathology 25:247-52. 132. Radkov, S. A., R. Touitou, A. Brehm, M. Rowe, M. West, T. Kouzarides, and M. J. Allday. 1999. Epstein-Barr virus nuclear antigen 3C interacts with histone deacetylase to repress transcription. J Virol 73:5688-97. 133. Richardson, A. 1997. Is breast cancer caused by late exposure to a common virus? Med Hypotheses 48:491-7. 134. Rickinson, A. B., and E. Kieff. 2001. Epstein-Barr virus, p. 2575-2627. In D. M. Knipe and P. M. Howley (ed.), Fields' virology 4th ed, vol. 2. Lippincott Williams & Wilkins, Philadelphia, Pa 135. Riese, D. J., 2nd, and D. F. Stern. 1998. Specificity within the EGF family/ErbB receptor family signaling network. Bioessays 20:41-8. 136. Robertson, E. S., J. Lin, and E. Kieff. 1996. The amino-terminal domains of Epstein-Barr virus nuclear proteins 3A, 3B, and 3C interact with RBPJ(kappa). J Virol 70:3068-74. 137. Robertson, E. S., B. Tomkinson, and E. Kieff. 1994. An Epstein-Barr virus with a 58-kilobase-pair deletion that includes BARF0 transforms B lymphocytes in vitro. J Virol 68:1449-58. 138. Roose, J., and H. Clevers. 1999. TCF transcription factors: molecular switches in carcinogenesis. Biochim Biophys Acta 1424:M23-37. 139. Ruf, I. K., P. W. Rhyne, C. Yang, J. L. Cleveland, and J. T. Sample. 2000. Epstein-Barr virus small RNAs potentiate tumorigenicity of Burkitt lymphoma cells independently of an effect on apoptosis. J Virol 74:10223-8. 140. Ryo, A., M. Nakamura, G. Wulf, Y. C. Liou, and K. P. Lu. 2001. Pin1 regulates turnover and subcellular localization of beta-catenin by inhibiting its interaction with APC. Nat Cell Biol 3:793-801. 141. Sadler, R. H., and N. Raab-Traub. 1995. Structural analyses of the Epstein-Barr virus BamHI A transcripts. J Virol 69:1132-41. 142. Satoh, S., Y. Daigo, Y. Furukawa, T. Kato, N. Miwa, T. Nishiwaki, T. Kawasoe, H. Ishiguro, M. Fujita, T. Tokino, Y. Sasaki, S. Imaoka, M. Murata, T. Shimano, Y. Yamaoka, and Y. Nakamura. 2000. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat Genet 24:245-50. 143. Schlessinger, J. 2004. Common and distinct elements in cellular signaling via EGF and FGF receptors. Science 306:1506-7. 144. Scholle, F., K. M. Bendt, and N. Raab-Traub. 2000. Epstein-Barr virus LMP2A transforms epithelial cells, inhibits cell differentiation, and activates Akt. J Virol 74:10681-9. 145. Schroder, W., N. Kienzle, G. Bushell, and T. Sculley. 2002. Antiserum raised against the Epstein-Barr virus BARF0 protein reacts to HLA-DR beta chain. Arch Virol 147:723-9. 146. Shackelford, J., C. Maier, and J. S. Pagano. 2003. Epstein-Barr virus activates beta-catenin in type III latently infected B lymphocyte lines: association with deubiquitinating enzymes. Proc Natl Acad Sci U S A 100:15572-6. 147. Shackelford, J., and J. S. Pagano. 2004. Tumor viruses and cell signaling pathways: deubiquitination versus ubiquitination. Mol Cell Biol 24:5089-93. 148. Sheen, T. S., Y. T. Huang, Y. L. Chang, J. Y. Ko, C. S. Wu, Y. C. Yu, C. H. Tsai, and M. M. Hsu. 1999. Epstein-Barr virus-encoded latent membrane protein 1 co-expresses with epidermal growth factor receptor in nasopharyngeal carcinoma. Jpn J Cancer Res 90:1285-92. 149. Shimizu, N., H. Yoshiyama, and K. Takada. 1996. Clonal propagation of Epstein-Barr virus (EBV) recombinants in EBV-negative Akata cells. J Virol 70:7260-3. 150. Shtutman, M., J. Zhurinsky, I. Simcha, C. Albanese, M. D'Amico, R. Pestell, and A. Ben-Ze'ev. 1999. The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci U S A 96:5522-7. 151. Sinclair, A. J., I. Palmero, G. Peters, and P. J. Farrell. 1994. EBNA-2 and EBNA-LP cooperate to cause G | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/25300 | - |
dc.description.abstract | EB病毒(Epstein-Barr virus)是一種普遍存在的人類γ泡疹病毒,全世界超過95%的成人均受過EB病毒的感染。EB病毒與一些惡性腫瘤有關,包括了伯奇氏淋巴瘤、霍奇金氏淋巴癌、鼻咽癌等。乳癌(Breast cancer)是女性最常被診斷出來惡性腫瘤之一,近年來許多實驗室研究結果顯示EB病毒可能也與乳癌的病變有所關係。由我們實驗室之前的研究顯示,在140個乳癌檢體中有66個(47.14%)可偵測到EB病毒基因的存在,而在12個乳癌組織旁的正常組織中只有1個(8.3%)偵測到EB病毒基因的存在,表示EB病毒基因主要在癌組織中被偵測到。經由生統分析之後,顯示EBV的存在與乳癌的預後較差有關。所以我們推斷EB病毒可能會促進乳癌的癌化情形。
為了研究EB病毒在乳癌中所扮演的角色,我們建立了EB病毒所感染的兩株乳癌細胞株,MCF7-A與BT474-A。在EB病毒所感染的乳癌細胞株中,EB病毒表現了三個典型第一期潛伏期所存在的基因產物(EBNA1, EBER1與 BARF0)。EB病毒感染的MCF7-A與BT474-A細胞擁有更能夠在軟洋膠中細胞獨立生長的能力。HER2 (亦稱Neu, ErbB2) 是酪胺酸激酶(RTKs)中表皮細胞生長因子接受器(EGFR; HER1/ErbB1)家族中的一員,另包括了HER3(ErbB3)與HER4(ErbB4)。在20-30%的人類乳癌中,可發現HER2這個原致癌基因的基因放大與過度表現,而這樣的現象又會與乳癌病人的預後不好與存活率低有所關係。此外,EB病毒的感染可增強HER2與HER3基因的表現並進而形成異質二元體(Heterodimer)。HER2與HER3形成的異質二元體可以刺激磷酯肌醇激酶(PI3K)作用器Akt與絲裂原活化蛋白激酶(MAPK)-ERK的磷酸化。為了了解HER2/HER3在細胞獨立生長中所扮演的角色,細胞種在含有HER2抗體(Herceptin)、PI3K抑制劑(LY294002)或MEK抑制劑(U0126)的軟洋膠中。結果MCF7-A細胞在軟洋膠中細胞獨立生長的能力在有HER2抗體(Herceptin)、PI3K抑制劑(LY294002)或MEK抑制劑(U0126)存在下都被減弱。另一方面,Wnt蛋白在老鼠中被證明具有促使乳腺癌化的能力,並且很清楚的知道Wnt/β-catenin訊息傳導在大部份的乳癌中是被活化的。這些證據包括了在細胞質中增加的β-catenin蛋白與常在細胞核中可觀察到β-catenin蛋白,以及β-catenin下游的轉錄基因的表現,如cyclin D1。在我們的研究中顯示EB病毒感染乳癌細胞之後,可以增加細胞中的β-catenin表現與累積,並且活化 β-catenin的下游標的基因,例如c-MYC 與 cyclin D1。 接著我們想要了解在受EB病毒感染的乳癌細胞中是哪一個EB病毒的基因產物(EBNA1, EBER1與 BARF0)促進了HER2/HER3與β-catenin表現上升。結果我們利用大量表現BARF0基因與利用干擾性核醣核酸(siRNA)的方法來證明BARF0在MCF7與BT474細胞中能夠促進HER2/HER3與β-catenin的表現,並同時能促進細胞的癌化活性。由冷光報導基因的實驗(Luciferase reporter assay)中,我們發現在MCF7細胞中表現BARF0,可使帶有HER2和HER3起動子的在轉譯上活化9.1和8.3倍。且相較親代細胞,於穩定的BARF0轉殖的MCF7細胞能夠在軟洋膠中形成更多的群落。同時,我們發現BARF0能夠增強BT474細胞中MMP2的量。而且BARF0可以透過PI3K/AKT訊息傳遞來活化β-catenin途徑來促進細胞的侵犯與轉移能力。這些發現意味著BARF0可能藉由活化HER2/HER3以及β-catenin的訊息傳遞來達到增強乳癌細胞癌化的能力。 | zh_TW |
dc.description.abstract | Epstein-Barr virus (EBV) is a ubiquitous human γ-herpesvirus estimated to have infected about 95% of the adult population worldwide. EBV is associated with certain malignancies, such as Burkitt lymphoma, Hodgkin lymphoma and nasopharyngeal carcinoma. Several laboratories have reported recently that EBV may also be involved in the pathogenesis of breast carcinoma, the most frequently diagnosed malignancies in women. In our laboratory, the presence of the EBV genome in breast tumors (66/140, 47.14%) and in normal tissues adjacent to breasr tumors (1/12, 8.3%) indicated that EBV was mainly detected in tumors. After statistical data analysis, EBV was correlated with poor prognosis in breast cancer. It suggested that EBV might be related to the development of some breast carcinomas.
To investigate the potential role of EBV in breast cancer, we established EBV-infected breast cancer cell lines, MCF7-A and BT474-A. Three EBV latency genes (EBNA1, EBER1, and BARF0) were expressed in EBV-infected breast cancer cells and this pattern was typical of EBV latency I. EBV-infected MCF7-A and BT474-A cells exhibited increased anchorage-independent growth in soft agar. HER2 (also known as Neu, ErbB2) is a member of the epidermial growth factor receptor (EGFR; HER1/ErbB1) family of receptor tyrosine kinases (RTKs), which also includes HER3(ErbB3) and HER4(ErbB4). Amplification and overexpression of the HER2 proto-oncogene is observed in 20–30% of human breast cancers and is correlated with poor prognosis and decreased patient survival. Moreover, EBV infection enhances expression of HER2 and HER3 gene, and formation of HER2/HER3 heterodimer. HER2/HER3 heterodimer also stimulated phosphorylation of the phosphatidylinositol 3'-kinase (PI3K)-dependent effector kinase Akt, as well as that of the MEK-dependent mitogen-activated kinase (MAPK), extracellular signal-regulated kinase (ERK). To realize the role of HER2/HER3 in anchorage-independent growth, cells were seeded in the soft agar in the presence of an anti-HER2 antibody, herceptin, PI3K inhibitor LY294002 or the MEK inhibitor U0126. The ability of colony formation in soft agar was substantially reduced by either herceptin or the PI3K inhibitor LY294002 or the MEK inhibitor U0126 in MCF7-A cells. In the other hand, the oncogenic potential of Wnt proteins in the mammary gland has been amply demonstrated in mouse models, and it is clear that at least distal components of the Wnt/β-catenin pathway are activated in majority of breast carcinomas. The evidence for this includes elevated levels of cytoplasmic β-catenin, the frequent presence of β-catenin in the nucleus, and expression of transcriptional targets of β-catenin such as cyclin D1. In our study, EBV infection enhances expression and accumulation of β-catenin, and activates expression of β-catenin target genes, c-MYC and cyclin D1. Next, it was examined which of the three EBV genes expressed in these cells (EBNA1, EBER1 and BARF0) was responsible for HER2/HER3 and β-catenin expression. Consequently, we showed that BARF0 alone was sufficient to efficiently up-regulate HER2/HER3 and β-catenin expression and promoted tumorigenic activity in MCF7 and BT474 cells by both overexpression and small interfering RNA knock-down. According to the luciferase reporter assay, expression of BARF0 resulted in 9.1- and 8.3-fold transcriptional activation of the HER2 and HER3 promoter construct in MCF7 cells, respectively. Stably BARF0-tranfected MCF7 cells formed more colonies in soft agar than parental cells. Meanwhile, we found that BARF0 enhances the expression of MMP2 in BT474 cells. And then BARF0 promotes BT474 cells migration and invasion ability through activating β-catenin signaling by PI3K/AKT pathway. These findings imply that BARF0 is likely to enhance the breast cancer tumorigenic activity through activating HER2/HER3 and β-catenin signaling pathway. | en |
dc.description.provenance | Made available in DSpace on 2021-06-08T06:08:15Z (GMT). No. of bitstreams: 1 ntu-96-F90442010-1.pdf: 4460359 bytes, checksum: addf2ff0e5bfb0f75255bb3bf7d34c39 (MD5) Previous issue date: 2007 | en |
dc.description.tableofcontents | 口試委員會審定書 I
誌謝 II 中文摘要 III Abstract V Abbreviations VII Table of Contents X Chapter I – Overview and rationale 1 Part I – Epstein-Barr virus 2 Part II – EBV and breast cancer 8 Part III – HER2/neu 11 Part IV – Wnt/β-catenin pathway 14 Part V – Rationale and specific aims 16 Chapter II –EBV enhances tumorigenic activity in human breast cancer cells 17 1. Introduction 18 2. Materials and methods 22 2.1 Cell culture 22 2.2 Establishment of EBV-infected MCF7 and BT474 cells 22 2.3 Plasmids construction 22 2.4 Transformation of ECOS101 competent cells with plasmids 23 2.5 Large scale preparation of plasmid 24 2.6 Transfection and cell cloning 25 2.7 DNA extraction and genomic PCR 25 2.8 RT–PCR analysis 25 2.9 LightCycler real-time PCR 27 2.10 Western Blotting 27 2.11 Immunoprecipitation 28 2.12 MTT Assay 29 2.13 Anchorage-independent growth 29 2.14 Reporter gene assay 29 2.15 Nucleosome ELISA assay 30 2.16 Flow cytometry 31 2.17 Fractionation 31 2.18 Daul luciferase reporter assay 31 2.19 Immunofluorescence Assay 32 2.20 Migration Assay 32 2.21 Invasion Assay 33 3. Results 35 3.1 EBV-infected breast cancer cells display type I Latency 35 3.2 EBV enhances breast cancer cell growth rate and anchorage-independent growth 35 3.3 EBV infection leads to upregulation of HER2 and HER3 in breast cancer cells 36 3.4 ERK and PI3K are activated downstream HER2/HER3 signaling pathway to enhance tumorigenic activity in EBV-infected breast cancer cells 37 3.5 EBV-encoded BARF0 enhances HER2 and HER3 expression 38 3.6 BARF0 enhanced breast cancer cells growth in soft agar through HER2/HER3 signaling 40 3.7 EBV-infection enhances MCF7 and BT474 cells resistant to taxol induced apoptosis through inactivating cdc2 40 3.8 EBV infection results in increased expression and accumulation of β-catenin in breast cancer cells 42 3.9 EBV augments activation of the TOPFlash luciferase reporter by β-catenin in breast cancer cells 43 3.10 Expression of β-catenin were upregulated in MCF7-HA-BARF0 and BT474-HA-BARF0 cells 44 3.11 BARF0 enhances expression and signaling of β-catenin 44 3.12 BARF0 enhances migration and invasion ability of BT474 cells 46 3.13 BARF0 upregulates β-catenin signaling through PI3K/AKT pathway 46 4. Discussion 48 5. List of figures 53 Figure II-1. Detection of Epstein-Barr virus (EBV) genome by polymerase chain reaction (PCR) 53 Figure II-2. EBV-infected MCF7 and BT474 cells display type I latency viral gene expression profile 54 Figure II-3. Quantification of Epstein-Barr virus (EBV) load 55 Figure II-4. EBV infection enhances cell growth of breast cancer cells 56 Figure II-5. EBV infection enhances anchorage-independent growth of breast cancer cells 57 Figure II-6. EBV infection upregulates the expression of HER2 and HER3 58 Figure II-7. EBV infection stimulates ERK and Akt activation through HER2/HER3 signaling pathway 59 Figure II-8. The cell growth rate of MCF7-A cells was attenuated by Herceptin 60 Figure II-9. The anchorage-independent growth of MCF7-A cells was attenuated by trastuzumab, PI3K inhibitor LY294002 or ERK inhibitor U0126 61 Figure II-10. Expression of HER2 and HER3 were upregulated in MCF7-HA-BARF0 cells 62 Figure II-11. BARF0 upregulates the transcription of HER2 and HER3 in MCF7 cells 63 Figure II-12. HER2 and HER3 mRNA degradation in MCF7-HA-BARF0 and MCF7-Neor cells 64 Figure II-13. Herceptin inhibits activation of PI3K/Akt kinase and MAPK kinase in MCF7-HA-BARF0 cell 65 Figure II-14. EBV-infection enhances MCF7 and BT474 cells resistant to taxol induced apoptosis 66 Figure II-15. The cell-cycle distribution 67 Figure II-16. EBV-infection enhances MCF7 and BT474 cells resistant to taxol induced apoptosis through inactivating cdc2 68 Figure II-17. EBV infection increased accumulation of β-catenin in breast cancer cells 69 Figure II-18. EBV up-regulates β-catenin signaling in MCF7-A and BT474-A cells 70 Figure II-19. BARF0 up-regulates β-catenin in MCF7 and BT474 cells 71 Figure II-20. BARF0 up-regulates β-catenin signaling in MCF7 and BT474 cells 72 Figure II-21. BARF0 enhances expression and induces accumulation of β-catenin 73 Figure II-22. BARF0 enhances migration and invasion ability of BT474 cells 74 Figure II-23. BARF0 upregulates β-catenin signaling through PI3K/AKT pathway 75 Figure II-24. LY294002 inhibits MCF7-HA-BARF0 cells migration and invasion through inactivating PI3K/Akt pathway 76 Figure II-25. Model 77 Chapter IV– Conclusion and perspectives 78 Appendix 80 Appendix 1. Construction of pcDNA3-HA-BARF0 plasmid 81 Appendix 2. Construction of pcDNA3-EBERs plasmid 82 Appendix 3. Construction of pSuperpuroBARF0 plasmid 83 Appendix 4. Contruction of the expression plasmid, pET-21a-BARF0 84 Appendix 5. Electrophoretic analysis of the expression of BARF0 cDNA 85 References 86 Vita 112 | |
dc.language.iso | en | |
dc.title | EB病毒促進人類乳癌細胞癌化之研究 | zh_TW |
dc.title | EBV enhances tumorigenic activity in human breast cancer cells | en |
dc.type | Thesis | |
dc.date.schoolyear | 95-2 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 陳振陽,張久瑗,蔡錦華,李明學 | |
dc.subject.keyword | Epstein-Barr 病毒,BARF0,HER2,HER3,β-catenin,乳癌, | zh_TW |
dc.subject.keyword | Epstein-Barr Virus,BARF0,HER2,HER3,β-catenin,breast cancer, | en |
dc.relation.page | 111 | |
dc.rights.note | 未授權 | |
dc.date.accepted | 2007-07-18 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 生物化學暨分子生物學研究所 | zh_TW |
顯示於系所單位: | 生物化學暨分子生物學科研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-96-1.pdf 目前未授權公開取用 | 4.36 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。